Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). The
most frequently occurred radiation-related side effect is probably the radiation-induced oral
mucositis, which affects up to 100% of NPC patients receiving radiation therapy, especially
combined with chemotherapy. Significant weight loss caused by Oral mucositis will keep
patients in worse nutrition status and then to decline immune function, hematopoietic
function and repair function, which will influence the patient's quality of life, reduce the
tolerance of treatment, and affect treatment effect. At present, the guidelines at home and
abroad more and more emphasize that early nutrition treatment and intervention before
systemic malnutrition, also suggest nutrition treatment and intervention at the same time of
anti-tumor treatment. First choice of nutritional intervention is oral nutrition supplement.
Nutren® Optimum has a higher protein ratio and 50% of the protein sources were lactalbumin
and 50% casein. Lactalbumin is a high-quality protein, with the highest nutritional value
among a variety of proteins. A cup of 210ml's Nutren® Optimum contains 5g lactalbumin.
Nutren® Optimum also contains dietary fiber, vitamin E, monounsaturated fat, L-carnitine, 30
kinds of vitamins and minerals and other nutrients, which can provide a comprehensive and
balanced nutrition. This single center, open-label, randomized controlled clinical trial
selects Nutren® Optimum as oral nutritional support for interventional group while routine
diet guidance for control group, aiming to evaluate the efficacy and safety of early and
whole course nutritional support by Nutren® Optimum during intensity modulated radiation
therapy for nasopharyngeal carcinoma which can improve patients' nutritional state and
quality of life, reduce side effects and improve the tolerability and effectiveness of
antitumor treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Nestle Health Science (China) Ltd. Nestlé Health Science Spain